Timeline

Our milestones mark a series of events that reflect our successes and innovative breakthroughs.
Setting goals and meeting them are a critical part of our core values.

IMPORTANT MILESTONES
  • 2016
  • Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Zimeta to FDA

    San Francisco, CA (March 15, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  This is the final major technical section to be submitted for Zimeta. The Chemistry, Manufacturing, and Controls technical section was submitted in December 2015 and the Effectiveness technical section was submitted in February 2016.

    March 15, 2016
  • Submission to FDA re: Zimeta™

    Kindred Biosciences, Inc. (NASDAQ: KIN), announced the submission to FDA of the Effectiveness Technical Section of the New Animal Drug Application (NADA) for Zimeta™(dipyrone injection, KIND-012).

    February 11, 2016
  • 2015
  • SUBMISSION TO FDA

    Kindred Biosciences, Inc. (NASDAQ: KIN), announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application (NADA) for KIND-012.

    December 17, 2015
  • POSITIVE TOPLINE RESULTS FOR KINDREDBIO PILOT FIELD STUDY – FEVER

    Kindred Biosciences, Inc. (NASDAQ: KIN), announced positive topline results from its pivotal field study (KB0120) of KIND-012 for the control of pyrexia (fever) in horses. KIND-012 study meets primary endpoint with p This study, KB0120, was a multicenter, randomized, blinded, placebo-controlled pivotal study that enrolled 138 horses to assess the effectiveness of KIND-012. The primary endpoint was improvement (a 2°F or greater decrease in temperature from baseline) or resolution of fever (a return to normothermia (≤101.0°F)) at hour 6 following treatment. The success rate was approximately 75% in the KIND-012 group vs. approximately 20% in the placebo group (p < 0.0001). Based on preliminary review of the safety data, the drug appears to be well tolerated.

    November 16, 2015
  • POSITIVE RESULTS FOR KINDREDBIO PILOT FIELD STUDY – FEVER

    Kindred Biosciences, Inc. (NASDAQ: KIN), announced positive results from its pilot field study of KIND-012 for the control of pyrexia (fever) in horses. Randomized, Blinded, Placebo-Controlled Phase 2 Study Meets Its Primary Endpoint. This study, which is the equivalent of a Phase 2 study, was a randomized, blinded, placebo-controlled, crossover study that enrolled 31 adult horses. The primary endpoint was improvement or resolution of fever. In the first treatment period, the response rate was 66.7% in the KIND-012 group vs. 12.5% in the placebo group (p=0.0032). In the second treatment period, the response rate was 57.1% in the KIND-012 group vs. 0% in the placebo group (p=0.0019).


    Screen Shot 2016-07-18 at 12.24.07 AM

    March 16, 2015